STOCK TITAN
  1. Home
  2. News
  3. KALV

KalVista Pharmaceuticals Inc - KALV STOCK NEWS

Welcome to our dedicated news page for KalVista Pharmaceuticals (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KalVista Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KalVista Pharmaceuticals's position in the market.

News
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
Rhea-AI Summary
KalVista Pharmaceuticals presented real-world data revealing treatment delays, suboptimal outcomes, and anxiety linked to injectable treatments for Hereditary Angioedema (HAE) patients at AAAAI 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
none
-
News
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. presents positive data on phase 3 KONFIDENT trial for sebetralstat at AAAAI 2024, showcasing high efficacy with one dose, safety, and flexibility in dosing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
clinical trial
-
News
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces entry into UK Innovative Licensing and Access Pathway (ILAP) for sebetralstat, a plasma kallikrein inhibitor for hereditary angioedema. Late-breaking phase 3 data to be presented at 2024 AAAAI Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.13%
Tags
none
News
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces late-breaking phase 3 data for the KONFIDENT trial at the 2024 AAAAI Annual Meeting. The company presents multiple abstracts on Hereditary Angioedema attacks and treatment patterns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences clinical trial
-
News
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. announces the pricing of its underwritten public offering, expecting gross proceeds of $160.1 million. The offering includes common stock and pre-funded warrants, with an option for additional shares. The pre-funded warrants are immediately exercisable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
offering
-
News
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announces a public offering of common stock and pre-funded warrants to certain investors. The company plans to use the proceeds for the clinical development of its product candidate sebetralstat and other activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
offering
News
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces positive results from the phase 3 KONFIDENT clinical trial for sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). The trial showed statistically and clinically significant efficacy, with a favorable safety profile. Sebetralstat achieved symptom relief faster than placebo, with no serious adverse events. The Company plans to submit a new drug application to the U.S. FDA in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
clinical trial
-
News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (KALV) recently granted four newly-hired employees inducement options to purchase an aggregate of 42,000 shares of KalVista common stock. The options have an exercise price of $15.74 per share and vest over a four-year period. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
none
-
News
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces the publication of data on the first report of an oral, potent, and selective FXIIa inhibitor in the peer-reviewed scientific journal, Frontiers in Pharmacology. The article describes the pharmacology of a representative compound from KalVista’s portfolio of oral Factor XII inhibitors, including potent, selective inhibition of both FXII zymogen and FXIIa, blockage of KKS-mediated edema in preclinical HAE models in vivo, and high oral availability in multiple species. This demonstrates KalVista's scientific leadership in medicinal chemistry and KKS biology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
News
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) completes the targeted number of attacks in the Phase 3 KONFIDENT Clinical Trial for sebetralstat, with data readout expected in early 2024 and NDA filing in H1 2024. The company also achieved Orphan Drug Status in Switzerland and presented real-world patient data at scientific meetings. However, the second fiscal quarter ended with no revenue, increased R&D and G&A expenses, and a net loss of $27.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Stock KALV logo
KalVista Pharmaceuticals Inc

Nasdaq:KALV

KALV Rankings

#3007 Ranked by Market Cap
#326 Ranked by Stock Gains
N/A Ranked by Dividends

KALV Stock Data

501.62M
24.12M
1.14%
92.16%
13.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About KALV

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.